Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Study of Milademetan in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03671564
Recruitment Status : Completed
First Posted : September 14, 2018
Last Update Posted : October 29, 2019
Information provided by (Responsible Party):
Daiichi Sankyo, Inc. ( Daiichi Sankyo Co., Ltd. )

Brief Summary:
This is a Phase 1, multicenter, open-label study to evaluate safety, tolerability and pharmacokinetics of milademetan in Japanese patients with relapsed or refractory acute myeloid leukemia. The milademetan initial dose will be Level 1: 90 mg. No increase in the milademetan dose will be made in the same participant. Dose-limiting toxicity associated with milademetan occurring at each level will be assessed, and the maximum tolerated dose (MTD) will be decided using a modified continuous reassessment method (mCRM).

Condition or disease Intervention/treatment Phase
Acute Myeloid Leukemia Drug: Milademetan Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 14 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1, Open-label, Dose Escalation Study of Milademetan, an Oral MDM2 Inhibitor, to Assess Safety, Tolerability and Pharmacokinetics in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia
Actual Study Start Date : August 23, 2018
Actual Primary Completion Date : September 6, 2019
Actual Study Completion Date : September 6, 2019

Arm Intervention/treatment
Experimental: Dose Escalation - Milademetan
All participants enrolled for dose escalation receive a single oral dose of 90 mg milademetan, followed by escalated doses, based on mCRM with EWOC
Drug: Milademetan
Milademetan, an MDM2 inhibitor, is provided in capsules for oral administration
Other Name: DS-3032b

Primary Outcome Measures :
  1. Number of Participants with Dose Limiting Toxicities (DLTs) [ Time Frame: at approximately 28 days after start of treatment ]
  2. Number of Participants with treatment emergent adverse events (TEAEs) [ Time Frame: through completion of follow-up, within approximately 1 year ]

Secondary Outcome Measures :
  1. Maximum plasma concentration (Cmax) [ Time Frame: Cycle 1: Day 1, 2, 8, 14; Cycle 2: Day 1 (within approximately 29 days) ]
  2. Time to reach Cmax (Tmax) [ Time Frame: Cycle 1: Day 1, 2, 8, 14; Cycle 2: Day 1 (within approximately 29 days) ]
  3. Area under the drug concentration-time curve (AUC) to the last observable concentration (AUClast) [ Time Frame: Cycle 1: Day 1, 2, 8, 14; Cycle 2: Day 1 (within approximately 29 days) ]
  4. Trough plasma concentration (Ctrough) [ Time Frame: Cycle 1: Day 1, 2, 8, 14; Cycle 2: Day 1 (within approximately 29 days) ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   20 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Relapsed or refractory AML
  • AML for which no standard treatment is available
  • Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 to 2

Exclusion Criteria:

  • Acute Promyelocytic Leukemia
  • Chronic myelogenous leukemia in blast crisis (BCR-ABL fusion gene positive)
  • Presence of central nervous system involvement of leukemia or a history of primary central nervous system leukemia

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03671564

Layout table for location information
Japanese Red Cross Narita Hospital
Chiba, Japan, 286-0041
Kyusyu University Hospital
Fukuoka, Japan, 812-8582
Gifu Municipal Hospital
Gifu, Japan, 500-8513
Chugoku Central Hospital
Hiroshima, Japan, 720-0001
National Hospital Organization Kumamoto Medical Center
Kumamoto, Japan, 860-0008
Tenri Hospital
Nara, Japan, 632-8552
NTT Medical Center Tokyo
Tokyo, Japan, 141-8625
National Hospital Organization Disaster Medical Center
Tokyo, Japan, 190-0014
Sponsors and Collaborators
Daiichi Sankyo Co., Ltd.
Layout table for investigator information
Study Director: Clinical Study Leader Daiichi Sankyo, Inc.
Layout table for additonal information
Responsible Party: Daiichi Sankyo Co., Ltd. Identifier: NCT03671564    
Other Study ID Numbers: DS3032-A-J104
184054 ( Registry Identifier: JAPIC CTI )
First Posted: September 14, 2018    Key Record Dates
Last Update Posted: October 29, 2019
Last Verified: October 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address:
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Clinical Study Report (CSR)
Time Frame: Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.
Access Criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Daiichi Sankyo, Inc. ( Daiichi Sankyo Co., Ltd. ):
Escalation with overdose control (EWOC)
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Neoplasms by Histologic Type